scholarly journals PRESCRIPTION PATTERN IN OBESE AND NON-OBESE INFERTILE WOMEN WITH POLYCYSTIC OVARY SYNDROME IN A TERTIARY CARE HOSPITAL

2018 ◽  
Vol 11 (3) ◽  
pp. 53
Author(s):  
Asha Avirah Mm ◽  
Aswathy Alias ◽  
Manjusha Sajith ◽  
Vandana Nimbargi ◽  
Shivhar Kumdale
Keyword(s):  
Polycystic Ovary Syndrome ◽  
Polycystic Ovary ◽  
Clomiphene Citrate ◽  
Treatment Options ◽  
Tertiary Care ◽  
Care Hospital ◽  
Lifestyle Modifications ◽  
Ovary Syndrome ◽  
Infertile Women ◽  
Current Medication

 Objective: The objective of this study is to evaluate the treatment options for the management of obese and non-obese infertile women with polycystic ovary syndrome (PCOS).Methods: A prospective observational study was conducted with 75 infertile PCOS women. The demographic details, body mass index, menstrual patterns, and current medication related to infertility were noted. The collected data were statistically represented in terms of range, frequency tables, and standard deviation wherever appropriate.Results: A majority of the infertile PCOS women were aged 24–27 years with a mean age of 25.72±3.53 years, belonging to middle socioeconomic class (44%) and mostly found to be urban residents 68%. Most of the PCOS women were overweight (32%) and obese (21%) with irregular menstrual pattern (90.67%). In combination therapy, clomiphene citrate (CC) pre-treated with oral contraceptives (OC) (37.93%) was mostly given to obese PCOS patients followed by CC with metformin pre-administered with OC (31.03%), whilen on-obese PCOS patients were mostly administered CC with gonadotropins pre-treated with OC(44%). In single therapy, OC was mostly administered to both non-obese (90%) and obese PCOS patients (88.90%).Conclusion: This study concluded that most of the infertile PCOS women were overweight and obese, a major risk actor causing hyperandrogenicity. CC pre-treated with OC and metformin with CC pre-treated with OC were mostly prescribed to obese PCOS patients. Lifestyle modifications along with treatment are strongly recommended, especially in obese PCOS patients.

scholarly journals Use of letrozole versus clomiphene citrate combined with gonadotropins for ovulation induction in infertile women with polycystic ovary syndrome: a pilot study

2017 ◽  
Vol 6 (9) ◽  
pp. 4098 ◽  
Author(s):  
Amitoj Athwal ◽  
Ratnabali Chakravorty ◽  
Dipanshu Sur ◽  
Rupam Saha
Keyword(s):  
Polycystic Ovary Syndrome ◽  
Polycystic Ovary ◽  
Endometrial Thickness ◽  
Clomiphene Citrate ◽  
Prospective Trial ◽  
Serum Estradiol ◽  
Ovary Syndrome ◽  
Infertile Women ◽  
Ovulation Stimulation ◽  
Group Serum

Background: The aim of the study was to evaluate the efficacy of letrozole and clomiphene citrate (CC) in gonadotropin-combined for ovulation stimulation in women with polycystic ovary syndrome (PCOS). It was a prospective pilot study.Methods: This prospective trial included 124 patients of infertile women with PCOS. Letrozole dose of 5 mg/day (n = 65) or a CC dose of 100 mg/day (n = 59) was given on day 3 to day 7 of the menstrual cycle, combined with gonadotropin i.e. follicle stimulating hormone (FSH) at a dose 75 IU every day starting on day 7 and continued to day 9. Main outcome measures were occurrence of ovulation, number of mature follicles, serum estradiol (E2) and endometrial thicknesses on the day of human chorionic gonadotropin (hCG), and pregnancy rates.Results: The clinical profile including mean age, duration of infertility, BMI, baseline FSH, LH and E2 of patients belonging to both groups were comparable. The numbers of mature follicles (4.3±0.3 vs. 2.9±0.7) were significantly higher in letrozole+FSH group. Serum E2 levels on the day of hCG (301.78±85.7 vs. 464.7±72.9 pg/mL) were significantly lower in the letrozole+FSH group. Significant differences were found in endometrial thickness measured on the day of hCG in letrozole+FSH group (p=<0.0001). The rate of ovulation was higher in letrozole+FSH group and it was marginally statistically significant (p=0.040). The rate of pregnancy was slightly greater in the letrozole+FSH group (17.85% versus 13.33%), although not statistically significant.Conclusions: Letrozole in combination with FSH appears to be a suitable ovulation inducing agent versus CC with FSH in PCOS. This combination may be more appropriate in patients who are particularly sensitive to gonadotropin.

scholarly journals Clomiphene Citrate versus Letrozole for Induction of Ovulation in Infertile women having Polycystic Ovarian Syndrome (Randomized Controlled Trial)

2021 ◽  
Vol 4 (7) ◽  
pp. 01-09
Author(s):  
Abdel Rahman Mohammed Saleh ◽  
Mahmoud Youssef Ali Ahmed Abdalla ◽  
Nourhan Adel Abu Elfotouh Tantawy
Keyword(s):  
Menstrual Cycle ◽  
Polycystic Ovary Syndrome ◽  
Congenital Adrenal Hyperplasia ◽  
Polycystic Ovary ◽  
Endometrial Thickness ◽  
Clomiphene Citrate ◽  
P Value ◽  
Adrenal Hyperplasia ◽  
Ovary Syndrome ◽  
Infertile Women

Background: Polycystic ovary syndrome is a disorder but with unclear etiology that its diagnosis depends on exclusion of other etiologies with ovulatory disorders and androgen excess as congenital adrenal hyperplasia, 21-hydroxylase deficient non classic congenital adrenal hyperplasia (NCAH), adrenal or ovarian androgen-secreting tumors, disorders of adrenocortical dysfunction as Cushing’s disease, and abuse of androgenic or anabolic drugs. Polycystic ovary syndrome affects approximately 6-15% of women in reproductive age and constitutes 50% of the causes of infertility in women. Aim of the Work: To compare the efficacy of letrozole on ovulation induction to that of clomiphene citrate in women suffering polycystic ovary syndrome and the effect on the follicular maturation, endometrial thickness and pregnancy rate. This study was carried in the outpatient infertility clinic of Ain-Shams Maternity Hospital during the period from November 2020 till April 2021. Patients and Methods: This study included 80 infertile women diagnosed as having polycystic ovary syndrome. Women were randomized into two groups. Letrozole group (1) included 40 women who were given the aromatase inhibitor (Letrozole) orally in a 5mg dose daily from day 3 to day 7 of the menstrual cycle. While Clomiphene citrate group (2) included 40 women who were given the clomiphene citrate orally in 100mg dose daily from day 3 to day 7 of the menstrual cycle. All women were counseled and informed consent was obtained before recruitment. Results: In this study, ovulation rate was significantly more frequent in the Letrozole group (82.5%, 33 women reached ovulation successfully) than in Clomiphene citrate group (60%, 24 women reached ovulation successfully) within P value=0.024. Clomiphene citrate at a dose of 100mg showed more efficacies in the number of follicle ≥18mm than Letrozole at a dose of 5mg. In Letrozole group, the number of follicles (≥18mm in diameter) ranged from 1 to 2 with a Mean±SD= 1.4±0.65 and in Clomiphene citrate group, the number of follicles (≥18mm in diameter) ranged from 1 to 3 with a Mean±SD= 1.9± 0.41 (P value=0.0001). Conclusion: Letrozole can be considered as a first line treatment of anovulation in polycystic ovary syndrome. But, moreover studies including larger number of cases will further confirm the efficacy of letrozole versus clomiphene citrate in induction of ovulation, reaching to the optimum doses for aromatases inhibitors, more observation on endometrial thickness, incidence of pregnancy outcomes, incidence of abortion and incidence of congenital fetal malformations.

scholarly journals Pregnancy in an Infertile Woman with Polycystic Ovary Syndrome

KYAMC Journal ◽  
2017 ◽  
Vol 6 (2) ◽  
pp. 656-659
Author(s):  
Md Imtiajul Islam ◽  
Md Zulfikar Ali ◽  
Sayama Hoque
Keyword(s):  
Polycystic Ovary Syndrome ◽  
Polycystic Ovary ◽  
Clomiphene Citrate ◽  
Treatment Options ◽  
Oral Contraceptive Pill ◽  
Infertile Woman ◽  
Polycystic Ovaries ◽  
Ovary Syndrome ◽  
Metabolic Conditions ◽  
Ovarian Diathermy

Introduction: The most common cause of anovulatory infertility is polycystic ovary syndrome (PCOS). It is a syndrome of ovarian dysfunction associated with hyperandrogenism and polycystic ovary morphology. Several treatment options are available for women with infertility related to PCOS including weight reduction, clomiphene citrate, gonadotropins, laparoscopic ovarian diathermy, metformin and letrozole.Case Presentation: This is a case report of 32-year-old infertile female who was married for 12 years and tried ovulation induction drugs several times but failed to conceive. She was overweight, hirsute, oligomenorrheic and lastly amenorrheic. Investigations revealed altered ratio of FSH and LH, and polycystic ovaries on ultrasound. Patient was adviced to do regular physical exercise and prescribed metformin and combined oral contraceptive pill. After treatment restoration of regular menstruation occurred, weight reduced and patient became pregnant.Conclusion: Before choosing any treatment option for an infertile woman with PCOS proper control of abnormal metabolic conditions are necessary for a successful treatment outcome.KYAMC Journal Vol. 6, No.-2, Jan 2016, Page 656-659

scholarly journals Prospective observational study on prescribing pattern of infertility treatment options and their success rates in women with polycystic ovary syndrome at tertiary care teaching hospital

2021 ◽  
Vol 8 (12) ◽  
pp. 5860
Author(s):  
Rishitha Sanjana Abbagoni ◽  
Madhuri Mushan ◽  
Pooja Kosika ◽  
Prathyusha Vemula ◽  
Manognya Pattepura
Keyword(s):  
Folic Acid ◽  
Polycystic Ovary Syndrome ◽  
Teaching Hospital ◽  
Ovulation Induction ◽  
Polycystic Ovary ◽  
Treatment Options ◽  
Tertiary Care ◽  
Infertility Treatment ◽  
Ovary Syndrome ◽  
Prescribing Pattern

Background: Polycystic ovary syndrome or in shortcut PCOS previously called as Stein-Leventhal syndrome is a primary and major cause of anovulatory infertility in women of child bearing ages. 3 in every 5 women with PCOS have trouble getting pregnant. Various therapeutic options are available in managing several PCOS symptoms and in increasing chances of pregnancy. The aim of the study was to observe the prescribing pattern of infertility treatment options and their individual success rates.Methods: The study was conducted in out-patient department of obstetrics and gynaecology, tertiary care teaching hospital, Telangana, India. The study included women aged between 18-37 years who were seeking treatment for infertility due to PCOS. Patients were divided into two categories based on their age and treatment they received which was further grouped accordingly.Results: The frequency of infertility was found to be significantly higher among PCOS women of age group between 23-27 when compared to other age groups. Among infertility treatment options, ovulation induction drugs were mostly prescribed and among supplements folic acid and myo-inositol were widely prescribed as supplements as well as an adjuvant. Patients who received treatment with ovulation inducing drugs showed high success rate.Conclusions: Lifestyle modifications were chosen as primary therapeutic option. Ovulation induction drugs among infertility treatment options, folic acid and myo-inositol among supplements were the mostly prescribed medicines to treat or improve infertility in PCOS women. Ovulation inducing drugs showed high success rate.

Sign in / Sign up

Export Citation Format

Share Document